Moonman 👨‍🚀

never financial advice. only educated moon talk.🚀🌕🌖🌗🌘🌑🌒🌗🌖🌕🚀

[Moonman 👨‍🚀 @squeezetodamoon]

@Justin_Bons #tezos > cardano

[Justin Bons @Justin_Bons]

1/20) Cardano has been propped up by false promises & claims

Promising the moon while only delivering mediocrity

ADA is one of the oldest 2nd generation blockchains

Yet it is objectively the least capable compared to all of the competition

I will cover why in this thread:

[𝑉 ∝ 𝑛 2 @CitezenB]

“Tezos @Tezos is very similar to Bitcoin and Ethereum, but it has a way of upgrading itself, so that the software can become better over time, and the decision on how to upgrade is in the hands of it’s user-base”–Arthur Breitman, co-founder of Tezos #Bitcoin #Ethereum #Tezos $XTZ

[Stan @StanNRGY]

$NVAX Novavax got included into the US mix and match Booster trial!! 🇺🇸

@US_FDA approve it finally!!

https://t.co/VchIK2vuze

[Moonman 👨‍🚀 @squeezetodamoon]

@Futbolfan4evr @3YearLetterman @elonmusk

[Moonman 👨‍🚀 @squeezetodamoon]

@Rotten_AppleNY @3YearLetterman @elonmusk

[Moonman 👨‍🚀 @squeezetodamoon]

@MexicoVino @3YearLetterman @elonmusk

[Moonman 👨‍🚀 @squeezetodamoon]

@tbakergrizzly 2017

[Apollo @TezFast]

https://t.co/LXm1OYmWwT

[Apollo @TezFast]

Tezos Blockchain Achieves Milestone of 1000 TPS Following Irmin Performance Tweak - TheNewsCrypto https://t.co/HJ1a4bsYOY

[Moonman 👨‍🚀 @squeezetodamoon]

@tinamariebaby3 Jesus Christ you’re uninformed

[Moonman 👨‍🚀 @squeezetodamoon]

@thoxsey @Vincent_5 @GavinNewsom I’ve lived in both states for years. California is so so much better than Texas it’s not even close.

[White Turtle @WhiteTCapital]

All this positive news from around the world suggests $NVAX will soon receive a green light from the FDA as well. Analysts say the company will make at least $4-5 billion in 2022. Add in the company's $1.5 billion in cash and the stock seems way undervalued with its $3.7B in MC

[Stan @StanNRGY]

$NVAX FDA approval will likely come in May! $XBI

https://t.co/ULki0pSg7G

[White Turtle @WhiteTCapital]

$NVAX Research analysts at Jefferies Financial Group upped their Q2 2022 EPS estimates for Novavax. Jefferies Financial Group analyst R. Song now anticipates that the biopharmaceutical company will earn $6.94 per share for the quarter, up from their prior estimate of $4.34.

[Moonman 👨‍🚀 @squeezetodamoon]

@TheCryptoLark #tezos

[Tree News @TreeNewsFeed]

WHY TEZOS WANTS TO TAKE ON ETHEREUM - BLOOMBERG

https://t.co/lm1jycHfyQ

[Moonman 👨‍🚀 @squeezetodamoon]

@RyanSAdams #tezos by far

[Moonman 👨‍🚀 @squeezetodamoon]

@RyanSAdams Cardano